Pharmaceuticals, Biotechnology and Life Sciences
Cube Biotech and IBA Lifesciences join forces to advance research and production capabilities for the life science industry by leveraging its complementary strengths to deliver unparalleled solutions in protein purification and stabilization and to enable groundbreaking research in the field of challenging drug targets.
Moderna announced Monday business updates and progress across its pipeline of mRNA medicines, entering 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need, as it achieved $3-3.1B in product sales.
Clarivate has released the twelfth annual Drugs to Watch report, its guide to the therapies poised to redefine the future of healthcare, highlighting 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years.
Klinge Biopharma GmbH, the licensee and exclusive global commercialization rights holder for FYB203, Formycon’s biosimilar candidate to Eylea (Aflibercept),has signed a licensing agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. for the semi-exclusive commercialization of FYB203 in major parts of Europe and Israel. In parallel Formycon has signed an agreement with Teva under which Formycon will supply the finished product.
Three blockbuster-potential assets in late-stage clinical trials and four pivotal readouts expected in 2025; anticipate four commercial assets by 2028…
MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company)…
Oral Presentation Presented at ASH 2024 Showed Iopofosine I 131 Achieved an 83.6% ORR and Exceeded Primary and Secondary Efficacy…
– Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:…
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® +…
— One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to…